Neutralization of recombinant hirudin: some practical considerations.
Fareed
J
J
Department of Pathology, Loyola University Medical Center, Maywood, Illinois 60150.
Walenga
J M
JM
Hoppensteadt
D
D
Iyer
L
L
Pifarre
R
R
D000818:Animals; D001780:Blood Coagulation Tests; D016063:Blood Loss, Surgical / Q000517:prevention & control; D015942:Factor VIIa / Q000494:pharmacology / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control*; D006493:Heparin / Q000009:adverse effects; D024764:Hirudin Therapy; D006629:Hirudins / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D006629:Hirudins; D011993:Recombinant Fusion Proteins; D006493:Heparin; D015942:Factor VIIa